Patient: Female, 74 years old. Pathological Diagnosis: In the hyperplastic fibrous tissue of the "abdominal wall" and "l

**Conclusion**: Based on the immunohistochemical profile (Claudin18.2 2+, 80%; CK7+, CK19+, S100P+; hepatobiliary-pancreatic origin), this patient is a candidate for first-line chemotherapy combined with zolbetuximab, provided her performance status and organ function permit. --- ## Clinical Evidence & Efficacy ### Claudin 18.2 as a Therapeutic Target Claudin 18.2 is a tight junction protein expressed in normal gastric mucosa and retained in a significant proportion of gastric, gastroesophageal junction (GEJ), and pancreaticobiliary adenocarcinomas, with limited expression in normal tissues outside the stomach, reducing off-tumor toxicity risk [2]. In pancreatic ductal adenocarcinoma, claudin 18.2 overexpression has been documented, and gemcitabine has been shown to induce claudin 18.2 overexpression in pancreatic cancer cells, potentially enhancing zolbetuximab-induced antibody-dependent cellular cytotoxicity (ADCC) [2]. ### Key Phase III Trial Data | Trial | Population | Regimen | Key Results | |-------|-----------|---------|-------------| | **SPOTLIGHT** (NCT03504397) | CLDN18.2-positive (≥75% tumor cells moderate-to-strong membranous staining), HER2-negative, locally advanced unresectable or metastatic G/GEJ adenocarcinoma | Zolbetuximab + mFOLFOX6 vs. chemotherapy alone | Improved PFS (primary endpoint) and OS; response rates did not improve [3] | | **GLOW** (NCT03653507) | CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic G/GEJ adenocarcinoma | Zolbetuximab + CAPOX vs. chemotherapy alone | Positive results announced; full data pending [3] | ### Applicability to This Case - **Claudin 18.2 positivity**: The patient's tumor shows 2+ staining in 80% of cells, meeting the SPOTLIGHT/GLOW threshold (≥75% moderate-to-strong membranous staining) [2][3]. - **HER2 status**: Not reported in the immunohistochemistry panel. HER2 testing is essential before initiating therapy, as the zolbetuximab trials enrolled only HER2-negative patients [2]. - **Tumor origin**: The hepatobiliary-pancreatic origin suggested by CK7+/CK19+/S100P+/Arginase-1– is consistent with claudin 18.2 expression, which has been described in pancreaticobiliary primaries [2]. --- ## Dosing & Administration ### Recommended First-Line Regimen Based on the SPOTLIGHT trial, the following regimen is recommended for CLDN18.2-positive, HER2-negative disease [3]: | Component | Dose | Schedule | |-----------|------|----------| | **Zolbetuximab** | Loading dose: 800 mg/m² IV | Cycle 1, Day 1 | | | Maintenance: 600 mg/m² IV | Every 3 weeks (Day 1 of each subsequent cycle) | | **mFOLFOX6** | Oxaliplatin 85 mg/m² IV | Day 1 | | | Leucovorin 400 mg/m² IV | Day 1 | | | 5-FU 400 mg/m² IV bolus, then 2400 mg/m² IV over 46 hours | Day 1 | **Alternative**: Zolbetuximab + CAPOX (capecitabine 1000 mg/m² orally twice daily Days 1–14, oxaliplatin 130 mg/m² IV Day 1, every 3 weeks) per the GLOW trial [2][3]. ### Geriatric Considerations | Parameter | Recommendation | |-----------|---------------| | **Renal function** | Calculate CrCl (Cockcroft-Gault) before initiating oxaliplatin/capecitabine. Oxaliplatin is contraindicated if CrCl <30 mL/min. | | **Performance status** | ECOG 0–1 is typical for trial eligibility. If ECOG ≥2, consider dose-reduced regimens or best supportive care. | | **Nausea/vomiting prophylaxis** | Nausea/vomiting are the most frequent adverse events during the first zolbetuximab cycle [3]. Administer guideline-directed antiemetic prophylaxis (NK1 antagonist + 5-HT3 antagonist + dexamethasone). | --- ## Safety Profile ### Common Adverse Events | Adverse Event | Incidence | Management | |---------------|-----------|------------| | **Nausea/vomiting** | Most frequent, especially first cycle [3] | Antiemetic premedication; consider dose delay if Grade ≥3 | | **Neutropenia** | Chemotherapy-related | G-CSF support if febrile neutropenia | | **Peripheral neuropathy** | Oxaliplatin-related | Dose reduction or discontinuation if persistent Grade ≥2 | | **Fatigue** | Common | Supportive care | ### Contraindications - **Absolute**: Known hypersensitivity to zolbetuximab or any component of the regimen. - **Relative**: CrCl <30 mL/min (oxaliplatin contraindicated); severe hepatic impairment. --- ## Guideline Recommendations | Source | Recommendation | Level | |--------|---------------|-------| | Austrian Consensus on Systemic Therapy (2024) | For CLDN18.2-positive tumors, combined treatment with mFOLFOX6 plus zolbetuximab can be recommended, if available [3] | Based on Phase III SPOTLIGHT data | | Canadian Consensus (2024) | CLDN18.2 testing should be rapidly incorporated into standard baseline pathological assessments [1] | Expert consensus | --- ## Critical Gaps in Current Evidence 1. **HER2 status unknown**: The patient's immunohistochemistry panel did not include HER2 testing. The zolbetuximab trials enrolled only HER2-negative patients. HER2 testing (IHC ± FISH) is mandatory before initiating therapy. 2. **Primary tumor site not definitively identified**: While the immunohistochemical profile suggests hepatobiliary-pancreatic origin, the SPOTLIGHT and GLOW trials enrolled G/GEJ adenocarcinoma. Data for zolbetuximab in pancreaticobiliary primaries are limited to ongoing phase II trials [2]. 3. **MSI/MMR and PD-L1 status not reported**: These biomarkers guide immunotherapy options (e.g., pembrolizumab for MSI-H/dMMR tumors; nivolumab + chemotherapy for PD-L1 CPS ≥5 per CheckMate-649) [2]. --- ## Conclusion For this 74-year-old female with CLDN18.2-positive (2+, 80%), HER2-untested metastatic adenocarcinoma of suspected hepatobiliary-pancreatic origin, the evidence supports first-line zolbetuximab plus mFOLFOX6 (or CAPOX) if HER2-negative status is confirmed and performance status is adequate. Nausea/vomiting prophylaxis and geriatric dose adjustments (CrCl assessment, start-low-go-slow) are critical. --- ### Further Diagnostic Suggestions (Reference Only) To enable a more accurate assessment, if available, please consider providing: - **HER2 IHC/FISH status**: Required to confirm eligibility for zolbetuximab-based therapy (trials excluded HER2-positive patients). - **MSI/MMR and PD-L1 CPS**: Determines eligibility for immunotherapy (pembrolizumab for MSI-H/dMMR; nivolumab + chemo for PD-L1 CPS ≥5). - **ECOG performance status and CrCl**: Critical for chemotherapy tolerability and dose selection in this geriatric patient. --- *This analysis is AI-generated based on retrieved literature and is intended for clinical reference only. Please verify all dosing and indications against the latest product prescribing information and apply individual patient judgment.*